愛污传媒

Skip to main content

Pfizer, Merck launch new trials of oral COVID-19 drugs

Share

Pfizer Inc. and Merck & Co. Inc. announced on Wednesday new trials of their experimental oral antiviral drugs for COVID-19 as the race to develop an easy-to-administer treatment for the potentially fatal illness heats up.

Pfizer said its latest mid-to-late-stage trial will enroll 1,140 non-hospitalized adults diagnosed with coronavirus infection who are not at risk of severe illness. Patients in the trial will be given Pfizer's pill, known as PF-07321332, and a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.

Pfizer's drug is designed to block the activity of a key enzyme that is needed for the coronavirus to multiply.

Merck said its new trial will study experimental drug molnupiravir for the prevention of COVID-19 among adults in the same household as someone diagnosed with symptomatic coronavirus infection. Merck and partner Ridgeback Biotherapeutics are already conducting a late-stage trial of the treatment in non-hospitalized patients to see if it reduces the risk of hospitalization or death.

Molnupiravir is a type of antiviral designed to introduce errors into the RNA of the virus that eventually prevent it from replicating.

Pfizer began in July a different trial of PF-07321332 in adults with COVID-19 infection who are at high risk of becoming severely ill due to underlying health conditions such as diabetes. The company said it expects initial results from that study some time this fall.

Rivals Pfizer and Merck, along with Swiss pharmaceutical Roche Holding AG, have made the most progress in developing what would be the first antiviral pill to treat, or possibly prevent, COVID-19.

To date, Gilead Sciences Inc.'s intravenous drug Veklury, known generically as remdesivir, is the only approved antiviral treatment for COVID-19 in the United States.

Roche and partner Atea Pharmaceuticals in June said early data from a trial of their experimental oral antiviral AT-527 showed that it lowered viral load in hospitalized patients.

Merck said in June that the U.S. government agreed to pay about $1.2 billion for 1.7 million courses of molnupiravir, if it is proven to work and authorized by regulators. The company said it expected to file for U.S. emergency use authorization of molnupiravir in the second half of 2021 at the earliest.

Pfizer said in July if the PF-07321332 trial was successful, it would file for a potential emergency use authorization in the fourth quarter.

(Reporting by Deena Beasley in Los Angeles; additional reporting by Amruta Khandekar; Editing by Vinay Dwivedi and Cynthia Osterman) 

CTVNews.ca Top Stories

The president and CEO of New Brunswick-based Covered Bridge Potato Chips is taking an 'extended leave of absence' after being charged with domestic violence this past weekend.

A memorial is growing outside a Walmart in Halifax after a 19-year-old employee was found dead inside an oven in the store Saturday night.

A search has started at Prairie Green Landfill for the remains of two victims of a serial killer.

He is a familiar face to residents of a neighbourhood just west of Roncesvalles Avenue.

Canada's discount airline is suspending operations to and from Saskatoon.

A new report suggests that Canadians' exposure to a radioactive gas is increasing, putting millions of people at a higher risk of developing lung cancer.

Local Spotlight

He is a familiar face to residents of a neighbourhood just west of Roncesvalles Avenue.

A meteor lit up our region's sky last night 鈥 with a large fireball shooting across the horizon over Lake Erie at around 7:00 p.m.

Residents of Ottawa's Rideauview neighbourhood say an aggressive wild turkey has become a problem.

A man who lost his life while trying to rescue people from floodwaters, and a 13-year-old boy who saved his family from a dog attack, are among the Nova Scotians who received a medal for bravery Tuesday.

A newly minted Winnipegger is hoping a world record attempt will help bring awareness for the need for more pump track facilities in the city.

A Springfield, Ont. man is being hailed a 'hero' after running into his burning home to save his two infant children.

Hortense Anglin was the oldest graduate to make her way across the platform at York University's Fall Convocation ceremony this week. At the age of 87, she graduated with an Honours degree in Religious Studies.

Looking for a scare with good intentions this Halloween season? The ghosts and ghouls of Eganville, Ont. invite families to tour the Haunted Walk at Lekbor Manor.

The image of a sleepy Saskatchewan small town with 'not a lot going on' is a well-known anecdote. However, one Saskatchewan company is hoping to change that 鈥 and allow communities both on and off the beaten path to share their stories and advertise what they have to offer.

Stay Connected